Compare NREF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | SGHT |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.5M | 309.6M |
| IPO Year | N/A | 2021 |
| Metric | NREF | SGHT |
|---|---|---|
| Price | $16.61 | $4.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $14.00 | $9.08 |
| AVG Volume (30 Days) | 58.9K | ★ 199.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.95% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | $10.47 | $10.39 |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.36 | $3.11 |
| 52 Week High | $17.22 | $9.24 |
| Indicator | NREF | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 43.14 |
| Support Level | $13.73 | $4.76 |
| Resistance Level | $17.22 | $5.25 |
| Average True Range (ATR) | 0.39 | 0.32 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 71.19 | 38.79 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.